Search PubMed⌕ Search

Biomedical subjects

F Sabbatini

Publications and source records attributed to F Sabbatini.

At least 37 records · Page 2Linked to original sources

Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial.

In a 6 to 12-week double-blind trial, the effect of cisapride (10 mg q.i.d.) was compared with that of placebo in 63 patients with esophagitis confirmed by endoscopy and/or biopsy. In only one patient (3%) in the cisapride group but in 43% of the placebo patients (p = 0.001), symptoms had not improved after 6 weeks. Forty patients continued treatment until week 12. At that time, control endoscopy showed a significantly (p = 0.005) higher rate of healing (no erosions, ulcers, or bleeding mucosa) in the cisapride patients (63%) than in the placebo patients (12%). At week 12, only three of the 21 cisapride patients still had moderate reflux symptoms, whereas eight of the 19 placebo patients had moderate or severe symptoms (p less than 0.05). Cisapride patients also took significantly (p less than 0.001) less antacids during the trial. These results show that cisapride, 10 mg q.i.d., heals esophagitis lesions and greatly reduces associated symptoms. The treatment was well tolerated.

Adult↗

[Tardive dyskinesia].

Neuroleptic drug treatment can produce tardive dyskinesia of which the incidence, risk factors, clinical characteristics and problems of differential diagnosis are described. Possible therapeutic approaches are then considered in the light of the hypothesis that the condition may derive from a physiopathological hypersensitivity of the dopamine receptors.

Antipsychotic Agents↗

Long-term ambulatory gastric pH monitoring: validation of a new method and effect of H2-antagonists.

A new ambulatory monitoring system was evaluated for long-term measurements of gastric acidity. A close correlation was observed between values indicated by the pH electrode of the system and the pH of simultaneously aspirated gastric juice, suggesting that the electrode signaled the pH of the gastric fluid content. When the pH electrode was passed via an endoscope, and its bulb was placed against the corpus mucosa, a higher acidity was recorded as compared with gastric juice. To test whether the electrodes measured mucosal pH during ordinary test conditions, the readings of pH probes with mechanically shielded bulbs that did not come into direct contact with the mucosa were compared with those of nonshielded probes in identical positions. Similar results were observed, supporting the hypothesis that nonshielded probes measured the pH of gastric contents rather than that of the mucosa. The importance of a standardized electrode position and a fixed meal schedule was demonstrated in simultaneous recordings of antral and fundic pH. Under fasting conditions, acidity was similar in both regions. After ingestion of a meal, gastric contents were more alkaline in the fundus than in the antrum. A wide range of 24-h acidity (19-83 mmol/L) was detected in 25 healthy subjects. The day-to-day reproducibility of the method as revealed in two consecutive 24-h tests was good. The effect of cimetidine and ranitidine on gastric acidity was evaluated in 9 subjects in a double-blind, double-dummy trial. Mean 24-h H+ activity was 37.4 +/- 4.6 mmol/L under placebo medication. It was lower with cimetidine, two doses of 400 mg (23.8 +/- 4.0); cimetidine, four doses of 400 mg (10.2 +/- 3.0); ranitidine, two doses of 150 mg (10.3 +/- 3.6), and two doses of 300 mg (10.0 +/- 3.5), respectively. In conclusion, ambulatory long-term pH monitoring is a suitable method to assess the physiologic pattern of gastric acidity and the effect of antisecretory drugs.

Adolescent↗

Distribution of intraventricular salmon calcitonin and suppression of gastric secretion.

Intracerebroventricularly (ICV) administered [125I] salmon calcitonin (sCT) was rapidly transported to the blood, but the permeability of the blood-brain barrier to sCT was low. ICV injected intact [125I]sCT was predominantly deposited in the periventricular mesencephalon and in the kidneys, and intravenously (IV) injected [125I]sCT in the kidneys, respectively. After both ICV and IV administration [125I]sCT was not retained by the stomach in large amounts. ICV and subcutaneously (SC) injected sCT caused suppression of gastric secretion volume, and of acid and pepsin outputs; the potency ratios between half maximal inhibitory amounts of sCT administered SC and ICV were 161, 252 and 13, respectively. On the other hand, perfusion of isolated whole mouse stomachs with sCT did not affect basal or stimulated acid and pepsin secretion. These findings indicate that sCT inhibits gastric acid secretion via receptors localized in the hypothalamus and in adjacent areas of the brain.

Animals↗

Comparison of pirenzepine and carbenoxolone in the treatment of chronic gastric ulcer. A double-blind endoscopic trial.

The purpose of the present study was to compare the effectiveness of pirenzepine and carbenoxolone in accelerating the healing of chronic gastric ulcer. Sixty-six out-patients with endoscopically proven gastric ulcer, without major systemic diseases, were admitted to the study. Patients were randomly allocated to either pirenzepine, 50 mg three times a day for 6 weeks, or carbenoxolone, 100 mg three times a day for one week followed by 50 mg three times a day for the remaining five weeks. At 6 weeks, the ulcers had healed in 20 out of 34 patients (59%) treated with pirenzepine, and in 15 out of 29 patients (52%) treated with carbenoxolone. Symptomatic improvement was similar with both drugs. Some major side effects (oedema, hypokalaemia and hypertension) occurred in approximately 30% of patients treated with carbenoxolone; of those receiving pirenzepine 25% complained of minor symptoms (e.g. dry mouth, headache, tachycardia). It is concluded that pirenzepine and carbenoxolone are of similar, but rather limited, efficacy in speeding the healing of chronic gastric ulcer, but show important differences with respect to tolerability.

Anti-Ulcer Agents↗

[Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].

In Parkinson's disease the decrease of dopamine in the nigro-striatal pathway is allied to modifications of other neuromodulation systems. The biochemical disorder of cholinergic, gabaergic and epinephrinergic pathways is present. Moreover the alteration of certain neuropeptides such as endorphins or enkefalins have been found. The Authors analyse the functional repercussions of these important biochemical modifications in the T.I.D.A. tract. In particular the variation of PRL synthesis and secretion due to dopamine deficiency during basal conditions and after pharmacological treatment is discussed.

Benserazide↗

[Diagnostic problems in impotence].

Every time we see a patient who is complaining of erectile failure we have to evaluate with proper exams the possible organic causes of this dysfunction. After having excluded the organic etiology we can speak of psychogenic impotence. The Authors describe a mixed type case and point out that a strict division between organic and psychological causes it's not always possible; besides it's better to try to understand the patient in his total structure.

Adult↗

Ranitidine vs cimetidine: short-term treatment of gastric ulcer.

We compared the clinical effectiveness and endoscopic results of ranitidine and cimetidine treatment; 71 outpatients, all affected with benign gastric ulcer, were selected for the study (43 type I, 7 type II and 21 type III, according to Johnson's classification). The patients were treated randomly for 4 weeks with ranitidine (300 mg daily) or cimetidine (1 g daily). An endoscopic examination was repeated within 3 days after the end of the treatment. Clinical checks were performed weekly in order to monitor the clinical course of pain and antacid consumption, according to the patient's needs. The patients who did not demonstrate complete healing on endoscopic examination were treated for an additional 4 week period. At the end of this 4 week period, another endoscopic examination was done. Thirty-six patients treated with ranitidine and 33 with cimetidine completed the first period of therapy. The two groups were homogeneous with regard to sex, age, duration of disease, smoking habits, alcohol consumption, and type and size of ulcer. Ranitidine and cimetidine treatments did not demonstrate any significant difference with regard to ulcer healing after the 4th or the 8th week of therapy. Both ranitidine and cimetidine were less effective in healing type I than type II and III G.U., at the 4th week of treatment. No significant differences between the two groups were noted with regard to pain or weekly antacid consumption. No significant side effects were reported.

Adult↗

Effects of propylthiouracil on MHV-3 virus mouse hepatitis.

A study was undertaken to observe the effect of propylthiouracil (PTU) on MHV-3 virus mouse hepatitis. PTU-treatment adversely influenced the course of the hepatitis. This effect was reflected by a significantly higher mortality rate, in spite of the absence of any significant difference of the plasma transaminase activity increase and of the liver virus content.

Alanine Transaminase↗

Placebo controlled studies with ranitidine in duodenal ulcer.

171 duodenal ulcer patients were treated for four weeks with either ranitidine or placebo under double-blind conditions. 40 patients (monocentre study) received ranitidine (40 mg), or placebo t.d.s. with meals and 80 mg at bedtime. 131 patients (multicentre study) received ranitidine (150 mg), or placebo b.d. In the monocentre study endoscopy after 4 weeks of treatment showed complete healing in 83.3% of the ranitidine patients and 30.4% of those on placebo (P less than 0.01%). In the multicentre study the healing percentages were 79.4% and 30.4%, respectively (P less than 0.001). In both trials pain and antacid consumption decreased in patients taking ranitidine more than in patients on placebo. After 4 weeks in the double blind studies 13 of the 15 patients with unhealed ulcer in the monocentre study and 51 of 54 patients in the multicentre study received open treatment with ranitidine for another 4 week period. The overall healing percentages by the 8th week of treatment with ranitidine were 94.4% and 93.6% respectively. No serious side effects, or haematological changes were observed during the treatment with ranitidine.

Administration, Oral↗